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Section Editor: Andrzej BartkeAdipose tissue dysfunction occurswith aging and has systemic effects, including peripheral insulin resistance, ec-
topic lipid deposition, and inﬂammation. Fundamental agingmechanisms, including cellular senescence and pro-
genitor cell dysfunction, occur in adipose tissue with aging andmay serve as potential therapeutic targets in age-
related disease. In this review, we examine the role of adipose tissue in healthy individuals and explore how
aging leads to adipose tissue dysfunction, redistribution, and changes in gene regulation. Adipose tissue plays a
central role in longevity, and interventions restricted to adipose tissue may impact lifespan. Conversely, obesity
may represent a state of accelerated aging.We discuss the potential therapeutic potential of targeting basic aging
mechanisms, including cellular senescence, in adipose tissue, using type II diabetes and regenerativemedicine as
examples.Wemake the case that aging should not be neglected in the study of adipose-derived stem cells for re-
generative medicine strategies, as elderly patients make up a large portion of individuals in need of such
therapies.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Cellular Senescence1. Adipose tissue: relevance in aging
Adipose tissue is a large and dynamic endocrine, immune, and re-
generative organ that can readily adapt to changes such as temperature,
nutrient availability, beta-adrenergic tone, and tissue damage in young,
healthy individuals. Adipose tissue is responsible for energy storage, nu-
trient sensing, and temperature regulation and has important functions
in immune modulation, wound healing, and tissue regeneration. Aging
is associated with a decline in tissue function and an increase in disease
burden, and adipose tissue is no exception. With aging, adipose tissue
undergoes signiﬁcant changes in abundance, distribution, cellular com-
position, and endocrine signaling, and plays a central role in the devel-
opment of insulin resistance, metabolic dysfunction, inﬂammation,
and impaired regenerative capacity with age (Fig. 1) (Tchkonia et al.,
2010). Several fundamental age-related changes occur at the cellular
level in adipose tissue that may contribute to age-related adipose dys-
function. Adipose tissue is often the largest organ, making up over 40%
of total body mass for example in women with BMI N35 (Bonora et al.,
1992; Romero-Corral et al., 2008). However even in lean individuals, ad-
ipose tissue has systemic inﬂuence on inﬂammatory signaling and insu-
lin sensitivity through secretion of adipokines and adipose-derived
hormones (Tilg and Moschen, 2006). It can affect the function of otherne Kogod Center on Aging, 200
d).
. This is an open access article underorgans including muscle, bone, liver, and the brain. Adipose tissue is
also being turned to as a key source of mesenchymal stem cells, which
are being increasingly explored as therapeutics for multiple degenera-
tive diseases (Zuk et al., 2002). Many interventions that extend lifespan
in lower organisms andmammals have signiﬁcant effects in adipose tis-
sue, often through themodulation of nutrient availability (Huffman and
Barzilai, 2010; Picard and Guarente, 2005; Tchkonia et al., 2010). Fur-
thermore, when single-gene mutations found to extend lifespan in
lower animals are restricted to adipose tissue, similar lifespan extension
can be seen (Bluher et al., 2003; Giannakou et al., 2004). Dysfunction of
adipose tissue, such as that in obesity, is associated with a shortened
lifespan and increase in age-related disease prevalence, including can-
cer and dementia (Gilbert and Slingerland, 2013; Kivipelto et al.,
2005). The abundance of adipose tissue, along with its varied functions,
importance to whole-body physiology, and constellation of aging
changes, makes it a highly relevant organ for the study of aging. Further
understanding of aging adipose tissue could be valuable for the discov-
ery and testing of therapeutic strategies to target fundamental aging
processes and age-related disease.
2. Age-related changes in adipose tissue composition and function
2.1. Fat redistribution with aging
Through middle- or early old age (e.g., 40–65 years of age), body
mass and body fat percentage increase in both men and women (Guothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Adipose tissue changeswith aging.With aging, adipose tissue undergoes numerous changes, affecting distribution, inﬂammatory status, progenitor function, senescent cell burden,
deposition of lipid in ectopic sites, adipose-derived hormone production and action, miRNA processing, and brown and beige adipose function.
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underlie reduced insulin sensitivity with age (Karakelides et al., 2010).
Frommiddle age, the distribution of adipose tissue shifts from primarily
subcutaneous depots to visceral depots, which are more closely associ-
ated with development of metabolic syndrome and insulin resistance
(Fox et al., 2007; Preis et al., 2010). In addition to metabolic effects, re-
distribution of adipose tissue is also partially responsible for esthetic
changes with aging that are related to subcutaneous fat loss, such as
sunken cheeks, thinning of the skin over the hands and legs, and in-
creased prominence of wrinkles (Coleman and Grover, 2006;
Donofrio, 2000).
The location and function of adipose tissue have been suggested
to be more important than the absolute amount of adipose tissue in
terms of its effect on insulin sensitivity (Jensen, 2008). It is also im-
portant to note that insulin resistance occurs even in individuals
with normal BMI, not only in obese individuals (McLaughlin et al.,
2004). Gluteofemoral adipose tissue is associated with increased in-
sulin sensitivity and lower diabetes and cardiovascular disease risk,
while increased waist circumference, which reﬂects visceral adipose
mass, is associated with insulin resistance and metabolic syndrome
(Manolopoulos et al., 2010; Snijder et al., 2003). In fact, waist to
hip ratio may be a better predictor of 5-year mortality than BMI
alone (Folsom et al., 1993). In the elderly, the ratio of limb fat to
trunk fat was found to correlate positively to insulin sensitivity,
while no differences in percent body fat or absolute amount of
trunk fat were found in the same groups (Gavi et al., 2007). Increased
limb:trunk fat ratio, but not limb fat or trunk fat independently, was
also correlated with higher levels of adiponectin, an adipose-derived
hormone associated with improved insulin sensitivity (Gavi et al.,
2007). This indicates that the distribution of adipose tissue may be
more important than the amount of adipose tissue in the regulation
of adiponectin levels.Subcutaneous and visceral adipose depots are very different in terms
of their effects on metabolism (Atzmon et al., 2002; Jensen, 2008;
Tchkonia et al., 2013a). In mice, transplantation of subcutaneous fat
into the visceral depot of recipient mice caused improvements in glu-
cose homeostasis as well as decreased body weight and fat mass,
whereas the opposite experiment, visceral adipose tissue transplanted
to the subcutaneous depot of recipient mice, had little effect (Tran
et al., 2008). Adipose tissue dysfunction is likely to originate in subcuta-
neous fat, which is a larger depot than visceral fat in young individuals.
With age, macrophages accumulate in subcutaneous fat, but no signiﬁ-
cant change is seen in visceral depots, which suggests that the sentinel
site of inﬂammation with aging is likely the subcutaneous fat
(Jerschow et al., 2007; Lakowa et al., 2015). Telomere length is also
shorter in subcutaneous versus visceral adipose tissue, independently
of BMI or diabetic status, and this difference is localized to the
stromovascular fraction, not adipocytes (Lakowa et al., 2015; Tchkonia
et al., 2006b). Accordingly, subcutaneous but not visceral adipose telo-
mere length shortens with aging, and also correlates with obesity and
diabetes (Lakowa et al., 2015). This shorter basal length and age-
related shortening of telomeres in subcutaneous depotsmaymake sub-
cutaneous adipose tissue a key contributor to increasing senescent cell
burden with aging. Because of the impact that subcutaneous fat has on
systemic metabolism, sentinel changes in subcutaneous fat with aging
could be the harbinger for metabolic dysfunction, and represent an op-
portunity for intervention that could have signiﬁcant impact on age-
related disease.
Identiﬁcation of the amount and distribution of adipose tissue that is
healthy in elderly individuals has been difﬁcult. Loss of subcutaneous fat
is a common feature with advancing age (Sepe et al., 2011). Although
visceral fat is associated with worse metabolic phenotypes in younger
individuals, the maintenance of adipose tissue seems to be beneﬁcial
in old age, sometimes independently of its location. For example, one
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their functional status had increased visceral andpericardial adipose tis-
sue, normally considered to be sites of ectopic lipid deposition, com-
pared to their “frail” counterparts (Idoate et al., 2015). However,
increased waist diameter was associated with the highest frailty within
each BMI category in another study, indicating that adipose distribution
favoring visceral adipose is still harmful when normalized for total adi-
pose tissue (Hubbard et al., 2010). The relationship between frailty and
BMI is U-shaped, with extremely low and extremely high BMI
predicting frailty and mortality (Allison et al., 1997; Blaum et al.,
2005; Hubbard et al., 2010). Interestingly, certain interventions that im-
prove frailty inmice alsomaintain adipose tissuemass (Xu et al., 2015a,
2015b).
2.2. Chronic, sterile inﬂammation
Sterile inﬂammation, or the presence of inﬂammation in the absence
of known, identiﬁable infection, is a common feature of aging and is cer-
tainly increased in aging adipose tissue. Adipose tissue is thought to be a
major contributor to the chronic, low-grade inﬂammation seen in aging
(Tchkonia et al., 2010; Wu et al., 2007). A variety of endogenous sub-
stances or stimuli, for example hypoxia, excess nutritional elements
such as fatty acids, or products of cell death, which is persistent at a
low level in obesity, may trigger sterile inﬂammation in adipose tissue
(Chen and Nunez, 2010; Itoh et al., 2011). Adipose-derived cytokines
and chemokines, termed adipokines, play a key role in immune cell re-
cruitment to adipose tissue. Adipose tissuemacrophages (ATMs) repre-
sent a signiﬁcant source of pro-inﬂammatory substances such as IL-6
with aging (Tilg and Moschen, 2006; Wu et al., 2007). Numbers of
ATMs increase in human subcutaneous fat until 30–35 years of age
and then slightly decline in lean individuals (Ortega Martinez de
Victoria et al., 2009). ATMs in visceral adipose tissue do not change sub-
stantially in number during aging, but the ratio of pro-inﬂammatoryM1
macrophages to anti-inﬂammatory M2 macrophages appears to in-
creasewith aging (Garg et al., 2014; Lumeng et al., 2011). Adipose tissue
T cell populations also change with aging. Speciﬁcally, CD4+ T-
lymphocytes, particularly regulatory T cells (Tregs), increase in visceral
adipose tissue in aging mice, along with an increase in CD8+ T-cells
(Lumeng et al., 2011). Senescent cells also accumulate signiﬁcantly
with age in adipose tissue. Through their senescence-associated secre-
tory phenotype (SASP), senescent cells are themselves the source of
many pro-inﬂammatory cytokines and chemokines (Lumeng et al.,
2011; Xu et al., 2015a, 2015b).
In addition to the chronic changes in adipose inﬂammatory signaling
and macrophage populations with aging, adipose tissue immune sys-
tem components can also undergo acute changes in response to nutri-
ent status, stress, or other short-term changes. For example, M2/M1
macrophage ratios have been shown to increase in response to a 24-h
fast in mice (Asterholm et al., 2012). Interestingly, these acute changes
are dampened in mice on a high fat diet, suggesting an impairment of
adipose tissue to respond to acute changeswhen undermetabolic stress
(Asterholm et al., 2012).
2.3. Progenitor cell function decline
Adipose tissue is composed ofmanydifferent cell types, generally di-
vided into two fractions: the adipocyte fraction (AF), which contains
primarily mature adipocytes, and the stromovascular fraction (SVF),
which comprises progenitor cells, lymphocytes, endothelial cells,
pericytes, and ﬁbroblasts. Adipose progenitor cells isolated from old in-
dividuals have reduced function and adipogenic potential compared to
progenitors isolated from their young counterparts (Caso et al., 2013;
Karagiannides et al., 2001; Tchkonia et al., 2010). This is also seen in pro-
genitors isolated from obese subjects when compared to lean age-
matched controls (Tchkonia et al., 2010).Preadipocytes acquire insulin sensitivity during differentiation to
adipocytes through increased expression of the critical transcription
factors peroxisome proliferator-activated receptor gamma (PPARγ)
and CCAAT/enhancer binding protein alpha (C/EBPα) (Hamm et al.,
1999). Preadipocytes that are less able to differentiate appear with
aging andmay contribute to the limited ability of adipose tissue to be in-
sulin responsive. This may be a signiﬁcant contributor to the insulin re-
sistance of old age, in addition to contributions from other organs (e.g.
pancreas, skeletal muscle, and liver) (Tchkonia et al., 2010).
Additionally, the replication and differentiation of preadipocytes is
crucial for hyperplasia and hypertrophy, the two ways that adipose tis-
sue responds to an increased demand for energy storage. Decline in
adipogenic potential has been postulated to drive insulin resistance by
limiting the ability of adipose tissue to expand in the face of excess nu-
trients (Danforth, 2000). In addition, inability to recruit progenitor cells
to the adipogenic lineage to execute hyperplasia can lead instead to hy-
pertrophy of existing adipocytes. The resulting increase in adipocyte
size has been associated with insulin resistance, especially in obesity
(Gustafson et al., 2015). Limited plasticity of adipose tissue with aging,
leading to adipocyte hypertrophy in the face of nutrient excess, may
be one mechanism by which older individuals are predisposed to insu-
lin resistance (Kim et al., 2014).
Targeting age-related changes in adipose tissue, such as cellular se-
nescence, has some promise in improving adipose progenitor function
(Xu et al., 2015a) and can prevent or reverse age-related fat loss in
mice (Xu et al., 2015a). Individuals with Hutchinson–Gilford progeria
syndrome suffer from lipodystrophy, which may be explained in part
by progenitor exhaustion in the adipose tissue (Mansilla et al., 2011;
Mazereeuw-Hautier et al., 2007). Similarly, mice with progeria have
dysfunctional progenitor cells and lipodystrophic features, which may
be attributable to progenitor dysfunction, cellular senescence, or im-
mune clearance of cells with persistent DNA damage (Baker et al.,
2008; Karakasilioti et al., 2013).
In addition to having implications for regenerative medicine, as will
be discussed, adipose progenitor cell function plays a crucial role in lipid
handling, adipose tissue expansion, and insulin sensitivity. Further
study is needed to understand the role that age-related adipose tissue
progenitor cell decline plays in age-related metabolic disease. Progeni-
tor cell function decline with age in other organs, such as skeletal mus-
cle, may also have contributory or independent roles in age-related
insulin resistance. The respective contributions of reduced adipogene-
sis, versus dysregulation of lipidmetabolismand/or glucosemetabolism,
to the development of age-related insulin resistance are unknown. In
addition, it is not known what percentage of progenitor cells become
dysfunctional with age, what threshold of progenitor dysfunction is
necessary to cause physiologic changes such as lipodystrophy or insulin
resistance, or whether progenitor dysfunction alone is sufﬁcient to
cause such changes (Kirkland and Dobson, 1997; Kirkland et al., 2002).
2.4. Cellular senescence
Adipose tissue is a site of considerable senescent cell accumulation,
in the settings of both obesity and aging (Tchkonia et al., 2010). Cellular
senescence is an essentially irreversible cell fate, in which cells stop di-
viding in response to an insult such as telomere shortening, oncogene
activation, or metabolic stress (Tchkonia et al., 2013b). Senescent cells
adopt an enlarged phenotype, exhibit positivity for senescence-
associated beta galactosidase, and can secrete a multitude of
chemokines, cytokines, growth factors, and matrix metalloproteinases,
comprising the SASP (Coppe et al., 2008). SASP factors are expressed
in vivo, as demonstrated in experiments where PAI-1 and IL-6 expres-
sion were increased in p16-positive cells isolated from mouse inguinal
fat (Baker et al., 2011). In addition, the SASP has been identiﬁed
in vivo in mousemodels of wound healing, liver ﬁbrosis, and embryonic
development (Demaria et al., 2014; Krizhanovsky et al., 2008; Storer
et al., 2013). The composition of the SASP may vary based on the
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further research.
In co-culture experiments, senescent cells have been shown to affect
the function of adipose-derived progenitors as well as impair insulin
sensitivity of adipose tissue (Xu et al., 2015a, 2015b). Therapeutic
targeting of the SASPmay be beneﬁcial in alleviating age-related insulin
resistance (Xu et al., 2015a, 2015b). We recently reported that remov-
ing senescent cells from older mice allows for improved adipogenesis
(Xu et al., 2015a). Removing senescent cells might therefore facilitate
adipose tissue expansion in the face of nutrient excess, concurrent
with improved insulin sensitivity, promoting a “metabolically healthy
obesity” phenotype. Indeed, adipose tissue expansion occurs in humans
after treatmentwith thiazolidinediones, which activate PPARγ, or JAK1/
2 inhibitors, which we recently reported to be SASP inhibitors (Xu et al.,
2015b), both of which improve insulin sensitivity (Fonseca, 2003;
Verstovsek et al., 2010), On the other hand, senescent cell removal
may allow for proper nutrient handling, mitochondrial function, and li-
polysis that would limit expansion. However, the effects of senescent
cell removal on adipose tissue dynamics have yet to be tested.
Strategies for selective elimination of senescent cells are beginning
to emerge (Roos et al., 2016; Zhu et al., 2015a, 2015b). These advances
follow the discovery that genetic clearance of senescent cells in mice
is effective in preventing or reversing age-related dysfunction including
loss of subcutaneous adipose tissue (Baker et al., 2011; Xu et al., 2015a).
Because strategies to eliminate senescent cells generally only remove a
portion of senescent cells, the effects of removing all senescent cells
from a tissue is unknown. However, reduction of 30–70% of senescent
cells does not appear to have detrimental effects on health of experi-
mental animals (Baker et al., 2011; Demaria et al., 2014). In addition,
several beneﬁcial roles of senescent cells have been identiﬁed, for exam-
ple in wound healing, which may have implications for adipose tissue
remodeling (Demaria et al., 2014). If they exist, detrimental effects of
senescent cell clearance could be avoided through the use of strategic,
intermittent treatment, which is possible with senolytic therapies
(Roos et al., 2016). This is in contrast to SASP inhibitors such as JAK1/2
inhibitors, which would need to be continually administered to exert
their effects. The high burden of senescent cells found in adipose tissue,
and its role at the nexus of aging, obesity, and insulin resistance, makes
adipose tissue senescence a promising target for alleviating age-related
metabolic dysfunction (Palmer et al., 2015; Tchkonia et al., 2013b).2.5. Ectopic lipid deposition
Aged preadipocytes are less able to differentiate and properly store
lipid, leading to a spillover of toxic free fatty acids that can cause ectopic
lipid deposition in sites such as the liver, muscle, and pancreas
(Cartwright et al., 2007; Guo et al., 2007; Marcus et al., 2010; Tchkonia
et al., 2006a). This inﬁltration of lipid into non-adipose tissues can
cause lipotoxicity and accelerate age-related disease. For example, ec-
topic lipid deposition may contribute to the increased prevalence of
non-alcoholic fatty liver diseasewith aging, in addition to other risk fac-
tors such as increased fasting glucose and serum triglycerides (Koehler
et al., 2012). In the pancreas, lipotoxicity can cause apoptosis of beta
cells, having a signiﬁcant impact on an individual's ability to produce in-
sulin (Unger and Zhou, 2001). Intermuscular adipose tissue, which in-
creases with aging, can contribute to declining muscle quality, a
feature of sarcopenia and frailty (Delmonico et al., 2009). Some have
proposed that the increase in visceral adipose tissue with aging is also
a type of ‘ectopic’ lipid deposition, resulting from overﬂow of toxic
free fatty acids due to the inability of subcutaneous depots to properly
store lipid due to age-related dysfunction (Jensen, 2008). Another site
of fat inﬁltration with age is the bone marrow, where adipocytes are
thought to have a negative impact on hematopoiesis, which could
have implications for bone marrow transplantation in patients of ad-
vanced age (Naveiras et al., 2009).2.6. Adipose-derived hormone secretion and sensitivity change with age
Prevalence of insulin resistance and type II diabetes risk increases
with age, mainly due to decreased peripheral insulin sensitivity and
age-related pancreatic beta cell dysfunction (Chen et al., 1985;
Defronzo, 1979). In addition to insulin resistance, aging predisposes to
resistance to other metabolic hormones, such as leptin. Leptin levels in-
crease with aging in rodents and humans, suggesting that leptin sensi-
tivity declines with age (Gabriely et al., 2002). Old rats given
recombinant leptin do not have a decrease in visceral fat, as occurred
in young rats, and do not suppress leptin gene expression in adipose tis-
sue as well as young rats (Ma et al., 2002). In contrast to other adipose-
derived hormones, adiponectin, which is produced by mature adipo-
cytes, is positively correlated with metabolic health. Adiponectin im-
proves preadipocyte differentiation and enhances insulin sensitivity
(Fu et al., 2005). Adiponectin levels decline with aging, but are positive-
ly correlated with longevity. For example, one study found that cente-
narians had higher levels of circulating adiponectin than BMI-matched
young controls (Atzmon et al., 2008). Adiponectin signaling has there-
fore been explored as a therapeutic target in obesity and diabetes
(Yamauchi and Kadowaki, 2013). More research is needed to determine
whether modulation of adipose-derived hormones could have an im-
pact on age-relatedmetabolic dysfunction or other age-related diseases.
2.7. Adipose tissue miRNA processing declines with age
Increased stochasticity in gene expression with aging occurs in sev-
eral tissues and may contribute to the loss of resilience, or ability to
properly respond to external stressors, with age (Raj and van
Oudenaarden, 2008). Differential expression of one particular class of
gene regulatory elements, microRNAs (miRNAs), is a generalized phe-
nomenon in aging and has been identiﬁed in multiple tissues including
adipose, brain, liver, and skeletal muscle (Pincus et al., 2011). Expres-
sion of Dicer, which processes miRNAs, declines with aging in the adi-
pose tissue of mice, the intestine (primary fat storage organ) of
C. elegans, and human preadipocytes (Mori et al., 2012). In mice, an
adipose-speciﬁc knockout of dicer, with reductions of dicer expression
in subcutaneous, perigonadal, and brown adipose tissues, caused
lipodystrophy. These mice exhibited decreased white adipose tissue
mass and “whitening” of the brown adipose tissue, aswell as inﬂamma-
tion and insulin resistance (Mori et al., 2014). Remarkably, dicer was
also found to be downregulated in patientswithHIV, who exhibit a sim-
ilar partial lipodystrophy syndrome. Caloric restriction, which extends
lifespan, prevented age-related downregulation of dicer, and knock-
down of dicer led to premature senescence in murine preadipocytes
(Mori et al., 2012). Downregulation of miRNAs may impair the ability
of adipose tissue to respond to metabolic stress or ﬂuctuation and may
play a role in age-related metabolic dysfunction. Therefore adipose
miRNA processing may represent a useful target for drugs that modu-
late fundamental aging processes and age-related metabolic disease
(Mori et al., 2012).
2.8. Brown and beige adipose changes with age
Although activation of brown adipose tissue is known to occur most
signiﬁcantly in response to cold exposure, it may also offer a defense
against age-relatedweight gain by increasing energy expenditure. A sig-
niﬁcant amount of functional brown fat is present in adult humans in
the interscapular fat depot (Cypess et al., 2009; van Marken
Lichtenbelt et al., 2009; Virtanen et al., 2009), which shares characteris-
tics of beige fat, rather than classical brown fat (Wu et al., 2012). UCP1
expression declines with aging in rodents in subcutaneous white fat,
suggesting that brown-like adipose tissue function (“beige” or “brite”
adipocytes) is reduced with aging (Rogers et al., 2012; Tan et al.,
2015). Additionally, brown fat itself may become dysfunctional with
age (Saito et al., 2009; Yamashita et al., 1999; Yoneshiro et al., 2011).
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humans, and its activation as measured by FDG-PET during cold expo-
sure is dampened in old versus young individuals (Saito et al., 2009).
Whether loss of brown-like features of adipose tissue might predict
the development of insulin resistance with aging is not clear. In mice,
age-related decline in BAT function is prevented by dietary restriction,
which is known to delay age-related dysfunction in other tissues
(Valle et al., 2008). Brown fat may play a role in preventing age-
related dysfunction and disease, but this remains to be established
(Mattson, 2010).
3. Adipose plays an integral role in longevity
3.1. Interventions that improve longevity impact adipose tissue
The majority of interventions that are known to affect lifespan, in-
cluding single gene mutations (e.g., in the GH/IGF-1 axis) and dietary
or pharmacologic interventions (e.g., caloric restriction, metformin,
rapamycin, 17α-estradiol, acarbose) affect fat tissue directly or indirect-
ly, often through pathways related to nutrient signaling or processing.
For example, growth-hormone-deﬁcient and -resistant mice, which ex-
hibit lifespan extension, have less ectopic lipid deposition, reduced cel-
lular senescence in adipose tissue, and improved adipose progenitor
function (Stout et al., 2014). Caloric restriction, which extends lifespan
in species ranging from ﬂies to primates, acts partially through a de-
crease in total adipose tissue mass, in addition to intracellular mecha-
nisms within adipose tissue such as decreasing inﬂammation,
increasing autophagy andDNA repairmechanisms, reducing cellular se-
nescence, and preventing age-related changes in gene expression
(Fontana and Klein, 2007; Linford et al., 2007). 17α-estradiol, which
has lifespan extension effects inmalemice, reduces inﬂammation in vis-
ceral adipose and decreases visceral adiposity (Stout et al., 2016). Met-
formin, which causes modest yet signiﬁcant lifespan extension in
rodents and may have lifespan-extending effects in humans, reduces
body mass in humans mainly through a decrease in adipose tissue
(Martin-Montalvo et al., 2013; Stumvoll et al., 1995). The effects of met-
formin on lifespan in humans have recently been demonstrated by a
surprising increase in survival of diabetic patients treated with metfor-
min beyond that of age-matched, non-diabetic controls (Bannister et al.,
2014). However, these data should be interpreted in light of a 4–9% rate
of undiagnosed type II diabetes in the general population over 65, the
onset of which can occur years before symptoms emerge or a diagnosis
is made (Harris et al., 1992; Menke et al., 2015). In sum, these examples
indicate that adipose tissue is a useful target for the development of
therapies to extend healthspan and alleviate or delay age-related
disease.
3.2. Adipose-speciﬁc interventions affect longevity
In lower animals, lifespan-extendingmutations that are restricted to
adipose tissue can confer the same lifespan extension as whole-
organism mutations (Katic et al., 2007). Other than the brain, adipose
tissue is arguably the only tissue in which organ-speciﬁc interventions
extend lifespan. For example, reduction of insulin/insulin-like growth
factor signaling speciﬁcally in the fat body of female Drosophila extends
lifespan (Giannakou et al., 2004). Fat-speciﬁc insulin receptor knockout
(FIRKO) mice are leaner and exhibit a signiﬁcant lifespan extension, as
also occurs in whole-body insulin receptor knockout animals (GIRKO).
Because FIRKO mice have similar food intake to WT mice, this suggests
that adiposity itself has some effect on longevity (Bluher et al., 2003).
Bariatric surgery, which causes caloric restriction and reduction in adi-
pose tissue mass, reduces mortality in severely obese individuals
(Sjostrom et al., 2007). Interestingly, it does not seem that surgical re-
moval of adipose tissue in humanshas the samebeneﬁts formetabolism
as reduction of adipose tissue by other methods such as caloric restric-
tion or exercise (Klein et al., 2004). However, these experiments havebeen focused on removal of subcutaneous fat by liposuction. The effects
of removing adipose from different depots, such as visceral adipose tis-
sue, may have different effects. For example in rats, selective surgical re-
moval of visceral adipose tissue increased median and maximum
lifespan (Muzumdar et al., 2008). Removal of omental adipose also
showed beneﬁcial effects on insulin sensitivity in healthy dogs (Lottati
et al., 2009). Experiments to remove omental adipose tissue in humans
were conducted in obese, diabetic individuals undergoing gastric bypass
surgery and did not ﬁnd additional beneﬁcial effect onmetabolic health
(Fabbrini et al., 2010; Herrera et al., 2010). However, it may be possible
that removal of visceral adipose tissue would be beneﬁcial in different
contexts, for example in aging or before the development of diabetes
(Tchkonia et al., 2013a). Therefore more research is needed to deter-
mine whether visceral adipose tissue is a useful target for interventions
to alleviate age-related metabolic diseases in humans (Huffman and
Barzilai, 2009). Similarly, little is known about the effects that interven-
tions to reduce adipose tissue mass or create negative energy balance,
such as exercise, bariatric surgery, or calorie restriction, may have on
markers of aging, for example cellular senescence. Research is under-
way to address these questions.
4. Obesity: accelerated aging?
4.1. Markers of aging increase in obesity
Several changes seen in aging adipose tissue also occur in the setting
of obesity. For example, plasma and adipose tissue from obese mice ex-
hibit increased oxidative stress compared to lean mice, and systemic
markers of oxidative stress are elevated in obese humans (Furukawa
et al., 2004). Adipose tissue from obese individuals also contains an in-
creased burden of senescent cells compared to lean age-matched con-
trols (Minamino et al., 2009; Tchkonia et al., 2010). In addition,
telomere shortening is found in white blood cells and in subcutaneous
adipose tissue from obese patients (Valdes et al., 2005). As in aging,
chronic, low-grade sterile inﬂammation of adipose tissue develops in
obesity, with elevated production of adipokines and decreased
adiponectin levels (Fernandez-Real et al., 2003). Brown adipose UCP1
expression also decreases in obesity and is lower in obese humans
with diabetes than obese humans without diabetes (Timmons and
Pedersen, 2009). More research is needed to determine the relationship
of these markers of aging to the development of obesity, namely to un-
derstand whether they have a pathogenic role in obesity, or whether
they are markers of established disease. Another interesting question
is whether or notmarkers of aging, for example senescent cell numbers,
are lower in individuals with “healthy” obesity versus obese individuals
with metabolic syndrome. Efforts to understand aging mechanisms in
adipose tissue may inform strategies to improve outcomes in obesity,
and vice versa.
4.2. Obesity predisposes to age-related diseases including cancer
Age is the leading risk factor for most chronic diseases, including de-
mentia, cardiovascular disease, type II diabetes, and cancer, even in lean
individuals. Age-related diseases are more prevalent in obese individ-
uals at younger ages than lean individuals, suggesting that obesity pre-
disposes to age-related disease and is in someways a state of premature
aging. Might adipose tissue dysfunction, seen in both aging and obesity,
be the common denominator? An increased understanding of adipose
tissue dysfunctionwith aging could help in understanding thepredispo-
sition to age-related diseases in obesity, and in identifying strategies to
prevent these comorbidities.
As in aging, there is a signiﬁcantly increased risk of cancer deaths in
obesity, and this is not due to an increase in hormonally regulated can-
cers alone (De Pergola and Silvestris, 2013; Samanic et al., 2004; Wolk
et al., 2001). Rather, it is due to a general increase in age-related cancers.
Individuals with a BMI over 40 have over 50% higher cancer death rates
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over 50 years old are estimated to be due to obesity (Calle et al., 2003).
Obesity-induced inﬂammation in adipose tissue may be one driver of
cancer risk, with certain adipokines (e.g., CCL2, VEGF, IL-6, and IL-8)
serving as chemoattractants that enhance migration of tumor cells and
support metastasis (Gilbert and Slingerland, 2013). In addition, senes-
cent cells, which increase in aging and obesity, are known to potentiate
tumorigenesis of epithelial cells, likely mediated by SASP components
(Laberge et al., 2015; Parrinello et al., 2005; Tchkonia et al., 2010).
These examples highlight how fundamental aging mechanisms that
occur with greater frequency in obesity could help to drive
tumorigenesis.
Interestingly, calorie restriction, which is known to decrease tumor
incidence in experimental animals, was unable to affect tumor inci-
dence when hunger signals were dampened by blocking neuroendo-
crine pathways (Minor et al., 2011). This hints that the relationship of
nutrient intake and cancer incidence is complicated andmay be affected
more by the post-absorptive state than has been previously appreciated.
Accelerated aging in obesity may not be solely due to the effects of nu-
trient excess and body composition, but may also be affected by mech-
anisms in place during the post-absorptive state.
5. Treating age-related adipose tissue dysfunction
5.1. Targeting age-related adipose tissue dysfunction in type II diabetes
Experimental strategies to target adipose tissue-speciﬁc mecha-
nisms such as macrophage inﬁltration and adipokine secretion have
shown some efﬁcacy in improvingmetabolic function in mousemodels
of diabetes (Kanda et al., 2006; Lumeng et al., 2007; Okada-Iwabu et al.,
2013). Senescent cell burden is increased in the adipose tissue of diabet-
ic patients, and senescent cells have been identiﬁed as a potentially use-
ful therapeutic target in type II diabetes, especially in the setting of novel
senolytic agents (Palmer et al., 2015; Tchkonia et al., 2013b; Xu et al.,
2015a; Zhu et al., 2015a, 2015b). On the other hand, some of the most
effective therapeutics for diabetes, especially metformin, have signiﬁ-
cant effects on fundamental aging mechanisms, and show lifespan-
extending effects in rodents (Martin-Montalvo et al., 2013). This impact
on longevity may also be present in humans as discussed previously
(Bannister et al., 2014). Treatment of age-related adipose tissue dys-
function may impact diabetes in several ways, for example prevention
of lipotoxicity by improving adipogenic capacity and lipid storage, or
improvement of peripheral insulin sensitivity by reducing pro-
inﬂammatory adipokine release.
5.2. Impact of aging on adipose-based regenerative strategies
Adipose-derived progenitors have been increasingly utilized in re-
generative medicine strategies, and could overtake bone marrow-
derived stem cells (BMSCs) as an abundant source of progenitor cells
(Strioga et al., 2012; Zuk et al., 2002). Adipose-derived mesenchymal
stem cells (ADSCs) have been suggested to be superior to BMSCs in
some orthopedic applications (Wyles et al., 2015). However, most stud-
ies of this typehave been conducted in subjects less than 60 years of age.
It is possible that effects of aging may complicate this picture, and that
strategies to mitigate effects of aging on these cells will need to be
employed to optimize their use in older individuals. Progenitors isolated
from different adipose depots within the same individual have different
properties, and these properties can be affected by aging (Schipper et al.,
2008; Tchkonia et al., 2013b). Aging is a signiﬁcant hurdle for the ad-
vancement of regenerative medicine strategies, because many patients
needing this type of interventionwill bemembers of the growing elder-
ly population. It is possible that age-modifying treatments will need to
be given to patients before isolating progenitor cells, or to cells in vitro
before being returned to the patient (Fig. 2). In the context of allogeneic
applications, transplantation of young or revitalized progenitor cellsinto old recipients may also have limited efﬁcacy due to the effects of
an aging microenvironment (Conboy et al., 2005).
For example, TGFβ familymembers interfere with stem cell function
and have been implicated in age-related progenitor dysfunction
(Carlson et al., 2009; Conboy et al., 2015). Amember of the TGFβ super-
family, activin A, increases in plasma with aging, and is secreted by se-
nescent adipose progenitor cells. Blocking activin A in vitro using
neutralizing antibodies or receptor blockers improves adipogenic po-
tential of adipose-derived progenitor cells (Xu et al., 2015a). JAK 1/2 in-
hibitors prevent activin A secretion by senescent cells, and reduce
circulating activin A in vivo, as does senescent cell elimination in old
INK-ATTAC mice (Xu et al., 2015a). JAK 1/2 inhibitors restored fat
mass and insulin sensitivity in oldmice, and also restored adipogenic ca-
pacity of adipose-derived progenitors to express transcription factors
necessary for differentiation (Xu et al., 2015a). Thus, TGFβ family mem-
bers secreted by senescent cells contribute to adipose-derived progeni-
tor dysfunction, and this is amenable to pharmacologic intervention.
Administration of therapies that target age-related dysfunction, for ex-
ample senolytics, to patients receiving transplanted cells may mitigate
host effects that could dampen the regenerative potential of
transplanted cells (Fig. 2) (Kirkland and Tchkonia, 2015; Zhu et al.,
2015a, 2015b).
Cell-free regenerative strategies represent a unique opportunity to
circumvent these aging “seed vs. soil” barriers by distilling the thera-
peutic potential of progenitor cells into deliverables not containing
cells. For example, secretome components or exosomes could be
administered, avoiding the use of cells isolated from aging patients
(Katsuda et al., 2013; Ranganath et al., 2012). More investigation of
these regenerative strategies is necessary to determine their efﬁcacy
in age-related disease.
Signiﬁcant work is needed in preclinical and human studies to char-
acterize ADSCs isolated from aged and obese individuals. Aging effects
on progenitor quality require more study, and potential therapeutics
to mitigate these effects to enhance regenerative potential should be
carefully tested in preclinical models. Understanding the effects that
aging has on regenerative capacity of progenitor cells as well as the po-
tential of a recipient to garner beneﬁt from these therapies will be es-
sential for application of regenerative medicine approaches to the
elderly population.6. Looking forward: adipose tissue as a therapeutic target in aging
Many classical aging mechanisms, for example cellular senescence,
chronic inﬂammation, and mitochondrial dysfunction, occur in adipose
tissue. Therefore, emerging interventions that target fundamental aging
mechanisms should have an effect on adipose tissue. This opens the
possibility of using adipose tissue as an indicator of the efﬁcacy of
such therapies. In addition, adipose tissue itself may prove to be a
worthwhile target for novel technologies that target fundamental
aging mechanisms. Therapies that extend lifespan and target funda-
mental aging mechanisms tend to have major effects on adipose tissue.
Conversely, it may be possible to use our knowledge of adipose tissue
aging in order to design therapies that speciﬁcally target aging mecha-
nisms that operate in fat. Because adipose tissue function is so intricate-
ly linked to insulin sensitivity and inﬂammation, targeting adipose
tissue aging could be a new frontier for therapies to combat age-
related type II diabetes, metabolic syndrome, and their complications.
Frailty and age-related fat loss could be other applications of therapies
that speciﬁcally target fundamental aging processes in adipose tissue.
Better understanding of adipose tissue aging and its effects on progeni-
tor cell function could also have broad implications for regenerative
medicine. Thus, adipose tissue aging is valuable for the study of basic
aging mechanisms, and is a potent therapeutic target for the develop-
ment of new therapies to combat effects of aging and age-related
disease.
Fig. 2. Possible points of intervention for adipose-derived stem cell therapies in aged individuals. Adipose-derived stem cells are becoming increasingly utilized in regenerative medicine.
Manypatientswhowould beneﬁt from such therapies are elderly, and the effects of aging on adipose tissue and progenitor functionmay reduce efﬁcacyof these therapies. Thismay bedue
to both inherent dysfunction of isolated progenitor cells and the aged microenvironment of the recipient. Strategies to mitigate effects of aging on these cells may need to be used to
optimize their use in older individuals. Points at which such strategies could be employed include (A) before isolating progenitor cells, (B) in vitro before returning cells to the patient,
and (C) in allogeneic applications, administration of age-modifying therapy to the recipient before transplantation of young or revitalized progenitor cells.
103A.K. Palmer, J.L. Kirkland / Experimental Gerontology 86 (2016) 97–105Acknowledgments
This work was supported by NIH grants AG13925 (JLK), AG041122
(JLK), AG31736 (Project 4: JLK), AG044396 (JLK), DK50456 (JLK), and
AG46061 (AKP), CTSA Grant Number TL1 TR000137 from the National
Center for Advancing Translational Science (NCATS), a Glenn/AFAR
Scholarship for Research in the Biology of Aging (AKP), the Connor
Group, the Glenn Foundation, the Ted Nash Long Life Foundation, and
the Noaber Foundation (JLK). AKP thanks the Mayo Clinic Medical
Scientist Training Program for providing an excellent training
environment.References
Allison, D.B., Faith, M.S., Heo, M., Kotler, D.P., 1997. Hypothesis concerning the U-shaped
relation between body mass index and mortality. Am. J. Epidemiol. 146, 339–349.
Asterholm, I.W., McDonald, J., Blanchard, P.G., Sinha, M., Xiao, Q., Mistry, J., Rutkowski,
J.M., Deshaies, Y., Brekken, R.A., Scherer, P.E., 2012. Lack of "immunological
ﬁtness" during fasting in metabolically challenged animals. J. Lipid Res. 53,
1254–1267.
Atzmon, G., Yang, X.M., Muzumdar, R., Ma, X.H., Gabriely, I., Barzilai, N., 2002. Differential
gene expression between visceral and subcutaneous fat depots. Horm. Metab. Res.
34, 622–628.
Atzmon, G., Pollin, T.I., Crandall, J., Tanner, K., Schechter, C.B., Scherer, P.E., Rincon, M.,
Siegel, G., Katz, M., Lipton, R.B., Shuldiner, A.R., Barzilai, N., 2008. Adiponectin levels
and genotype: a potential regulator of life span in humans. J. Gerontol. Ser. A Biol.
Med. Sci. 63, 447–453.
Baker, D.J., Perez-Terzic, C., Jin, F., Pitel, K.S., Niederlander, N.J., Jeganathan, K., Yamada, S.,
Reyes, S., Rowe, L., Hiddinga, H.J., Eberhardt, N.L., Terzic, A., van Deursen, J.M., 2008.
Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1
insufﬁciency. Nat. Cell Biol. 10, 825–836.
Baker, D.J., Wijshake, T., Tchkonia, T., LeBrasseur, N.K., Childs, B.G., van de Sluis, B.,
Kirkland, J.L., van Deursen, J.M., 2011. Clearance of p16Ink4a-positive senescent
cells delays ageing-associated disorders. Nature 479, 232–236.
Bannister, C.A., Holden, S.E., Jenkins-Jones, S., Morgan, C.L., Halcox, J.P., Schernthaner, G.,
Mukherjee, J., Currie, C.J., 2014. Can people with type 2 diabetes live longer than
those without? A comparison of mortality in people initiated with metformin or
sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes.
Metab.
Blaum, C.S., Xue, Q.L., Michelon, E., Semba, R.D., Fried, L.P., 2005. The association between
obesity and the frailty syndrome in older women: the Women's Health and Aging
Studies. J. Am. Geriatr. Soc. 53, 927–934.
Bluher, M., Kahn, B.B., Kahn, C.R., 2003. Extended longevity in mice lacking the insulin re-
ceptor in adipose tissue. Science (New York, N.Y.) 299, 572–574.
Bonora, E., Del Prato, S., Bonadonna, R.C., Gulli, G., Solini, A., Shank, M.L., Ghiatas, A.A.,
Lancaster, J.L., Kilcoyne, R.F., Alyassin, A.M., et al., 1992. Total body fat content and
fat topography are associated differently with in vivo glucose metabolism in
nonobese and obese nondiabetic women. Diabetes 41, 1151–1159.Calle, E.E., Rodriguez, C., Walker-Thurmond, K., Thun, M.J., 2003. Overweight, obesity, and
mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med.
348, 1625–1638.
Carlson, M.E., Conboy, M.J., Hsu, M., Barchas, L., Jeong, J., Agrawal, A., Mikels, A.J., Agrawal,
S., Schaffer, D.V., Conboy, I.M., 2009. Relative roles of TGF-beta1 and Wnt in the sys-
temic regulation and aging of satellite cell responses. Aging Cell 8, 676–689.
Cartwright, M.J., Tchkonia, T., Kirkland, J.L., 2007. Aging in adipocytes: potential impact of
inherent, depot-speciﬁc mechanisms. Exp. Gerontol. 42, 463–471.
Caso, G., McNurlan, M.A., Mileva, I., Zemlyak, A., Mynarcik, D.C., Gelato, M.C., 2013. Periph-
eral fat loss and decline in adipogenesis in older humans. Metab. Clin. Exp. 62,
337–340.
Chen, G.Y., Nunez, G., 2010. Sterile inﬂammation: sensing and reacting to damage. Nat.
Rev. Immunol. 10, 826–837.
Chen, M., Bergman, R.N., Pacini, G., Porte Jr., D., 1985. Pathogenesis of age-related glucose
intolerance in man: insulin resistance and decreased beta-cell function. J. Clin.
Endocrinol. Metab. 60, 13–20.
Coleman, S.R., Grover, R., 2006. The anatomy of the aging face: volume loss and changes in
3-dimensional topography. Aesthet. Surg. J. 26, S4–S9.
Conboy, I.M., Conboy, M.J., Wagers, A.J., Girma, E.R., Weissman, I.L., Rando, T.A., 2005. Re-
juvenation of aged progenitor cells by exposure to a young systemic environment.
Nature 433, 760–764.
Conboy, I.M., Conboy, M.J., Rebo, J., 2015. Systemic problems: a perspective on stem cell
aging and rejuvenation. Aging 7, 754–765.
Coppe, J.P., Patil, C.K., Rodier, F., Sun, Y., Munoz, D.P., Goldstein, J., Nelson, P.S., Desprez,
P.Y., Campisi, J., 2008. Senescence-associated secretory phenotypes reveal cell-
nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS
Biol. 6, 2853–2868.
Cypess, A.M., Lehman, S., Williams, G., Tal, I., Rodman, D., Goldﬁne, A.B., Kuo, F.C., Palmer,
E.L., Tseng, Y.H., Doria, A., Kolodny, G.M., Kahn, C.R., 2009. Identiﬁcation and impor-
tance of brown adipose tissue in adult humans. N. Engl. J. Med. 360, 1509–1517.
Danforth Jr., E., 2000. Failure of adipocyte differentiation causes type II diabetes mellitus?
Nat. Genet. 26, 13.
De Pergola, G., Silvestris, F., 2013. Obesity as amajor risk factor for cancer. J. Obes. 291546,
2013.
Defronzo, R.A., 1979. Glucose intolerance and aging: evidence for tissue insensitivity to in-
sulin. Diabetes 28, 1095–1101.
Delmonico, M.J., Harris, T.B., Visser, M., Park, S.W., Conroy, M.B., Velasquez-Mieyer, P.,
Boudreau, R., Manini, T.M., Nevitt, M., Newman, A.B., Goodpaster, B.H., Health, A.,
2009. Body. Longitudinal study of muscle strength, quality, and adipose tissue inﬁl-
tration. Am. J. Clin. Nutr. 90, 1579–1585.
Demaria, M., Ohtani, N., Youssef, S.A., Rodier, F., Toussaint, W., Mitchell, J.R., Laberge, R.M.,
Vijg, J., Van Steeg, H., Dolle, M.E., Hoeijmakers, J.H., de Bruin, A., Hara, E., Campisi, J.,
2014. An essential role for senescent cells in optimal wound healing through secre-
tion of PDGF-AA. Dev. Cell 31, 722–733.
Donofrio, L.M., 2000. Fat distribution: a morphologic study of the aging face. Dermatol.
Surg. 26, 1107–1112 ([et al]).
Fabbrini, E., Tamboli, R.A., Magkos, F., Marks-Shulman, P.A., Eckhauser, A.W., Richards,
W.O., Klein, S., Abumrad, N.N., 2010. Surgical removal of omental fat does not im-
prove insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenter-
ology 139, 448–455.
Fernandez-Real, J.M., Lopez-Bermejo, A., Casamitjana, R., Ricart, W., 2003. Novel interac-
tions of adiponectin with the endocrine system and inﬂammatory parameters.
J. Clin. Endocrinol. Metab. 88, 2714–2718.
104 A.K. Palmer, J.L. Kirkland / Experimental Gerontology 86 (2016) 97–105Folsom, A.R., Kaye, S.A., Sellers, T.A., Hong, C.P., Cerhan, J.R., Potter, J.D., Prineas, R.J., 1993.
Body fat distribution and 5-year risk of death in older women. J. Am. Med. Assoc. 269,
483–487.
Fonseca, V., 2003. Effect of thiazolidinediones on body weight in patients with diabetes
mellitus. Am. J. Med. 115 (Suppl. 8 A), 42S–48S.
Fontana, L., Klein, S., 2007. Aging, adiposity, and calorie restriction. J. Am. Med. Assoc. 297,
986–994.
Fox, C.S., Massaro, J.M., Hoffmann, U., Pou, K.M., Maurovich-Horvat, P., Liu, C.Y., Vasan, R.S.,
Murabito, J.M., Meigs, J.B., Cupples, L.A., D'Agostino Sr., R.B., O'Donnell, C.J., 2007. Ab-
dominal visceral and subcutaneous adipose tissue compartments: association with
metabolic risk factors in the Framingham Heart Study. Circulation 116, 39–48.
Fu, Y., Luo, N., Klein, R.L., Garvey, W.T., 2005. Adiponectin promotes adipocyte differenti-
ation, insulin sensitivity, and lipid accumulation. J. Lipid Res. 46, 1369–1379.
Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama,
O., Makishima, M., Matsuda, M., Shimomura, I., 2004. Increased oxidative stress in
obesity and its impact on metabolic syndrome. J. Clin. Invest. 114, 1752–1761.
Gabriely, I., Ma, X.H., Yang, X.M., Rossetti, L., Barzilai, N., 2002. Leptin resistance during
aging is independent of fat mass. Diabetes 51, 1016–1021.
Garg, S.K., Delaney, C., Shi, H., Yung, R., 2014. Changes in adipose tissue macrophages and
T cells during aging. Crit. Rev. Immunol. 34, 1–14.
Gavi, S., Feiner, J.J., Melendez, M.M., Mynarcik, D.C., Gelato, M.C., McNurlan, M.A., 2007.
Limb fat to trunk fat ratio in elderly persons is a strong determinant of insulin resis-
tance and adiponectin levels. J. Gerontol. Ser. A Biol. Med. Sci. 62, 997–1001.
Giannakou, M.E., Goss, M., Junger, M.A., Hafen, E., Leevers, S.J., Partridge, L., 2004. Long-
lived Drosophila with overexpressed dFOXO in adult fat body. Science (New York,
N.Y.) 305, 361.
Gilbert, C.A., Slingerland, J.M., 2013. Cytokines, obesity, and cancer: new insights on
mechanisms linking obesity to cancer risk and progression. Annu. Rev. Med. 64,
45–57.
Guo, S.S., Zeller, C., Chumlea, W.C., Siervogel, R.M., 1999. Aging, body composition, and
lifestyle: the Fels Longitudinal Study. Am. J. Clin. Nutr. 70, 405–411.
Guo, W., Pirtskhalava, T., Tchkonia, T., Xie, W., Thomou, T., Han, J., Wang, T., Wong, S.,
Cartwright, A., Hegardt, F.G., Corkey, B.E., Kirkland, J.L., 2007. Aging results in para-
doxical susceptibility of fat cell progenitors to lipotoxicity. Am. J. Physiol. Endocrinol.
Metab. 292, E1041–E1051.
Gustafson, B., Hedjazifar, S., Gogg, S., Hammarstedt, A., Smith, U., 2015. Insulin resistance
and impaired adipogenesis. Trends Endocrinol. Metab. 26, 193–200.
Hamm, J.K., el Jack, A.K., Pilch, P.F., Farmer, S.R., 1999. Role of PPAR gamma in regulating
adipocyte differentiation and insulin-responsive glucose uptake. Ann. N. Y. Acad. Sci.
892, 134–145.
Harris, M.I., Klein, R., Welborn, T.A., Knuiman, M.W., 1992. Onset of NIDDM occurs at least
4–7 yr before clinical diagnosis. Diabetes Care 15, 815–819.
Herrera, M.F., Pantoja, J.P., Velazquez-Fernandez, D., Cabiedes, J., Aguilar-Salinas, C.,
Garcia-Garcia, E., Rivas, A., Villeda, C., Hernandez-Ramirez, D.F., Davila, A., Zarain, A.,
2010. Potential additional effect of omentectomy on metabolic syndrome, acute-
phase reactants, and inﬂammatory mediators in grade III obese patients undergoing
laparoscopic Roux-en-Y gastric bypass: a randomized trial. Diabetes Care 33,
1413–1418.
Hubbard, R.E., Lang, I.A., Llewellyn, D.J., Rockwood, K., 2010. Frailty, body mass index,
and abdominal obesity in older people. J. Gerontol. Ser. A Biol. Med. Sci. 65,
377–381.
Huffman, D.M., Barzilai, N., 2009. Role of visceral adipose tissue in aging. Biochim.
Biophys. Acta 1790, 1117–1123.
Huffman, D.M., Barzilai, N., 2010. Contribution of adipose tissue to health span and lon-
gevity. Interdiscip. Top. Gerontol. 37, 1–19.
Idoate, F., Cadore, E.L., Casas-Herrero, A., Zambom-Ferraresi, F., Marcellan, T., Ruiz de
Gordoa, A., Rodriguez-Manas, L., Bastarrika, G., Marques, M.C., Martinez-Velilla, N.,
Vicente-Campos, D., Izquierdo, M., 2015. Adipose tissue compartments, muscle
mass, muscle fat inﬁltration, and coronary calcium in institutionalized frail nonage-
narians. Eur. Radiol. 25, 2163–2175.
Itoh, M., Suganami, T., Hachiya, R., Ogawa, Y., 2011. Adipose tissue remodeling as homeo-
static inﬂammation. Int. J. Inﬂamm. 720926, 2011.
Jensen, M.D., 2008. Role of body fat distribution and the metabolic complications of obe-
sity. J. Clin. Endocrinol. Metab. 93, S57–S63.
Jerschow, E., Anwar, S.A., Barzilai, N., Rosenstreich, D., 2007. Macrophages accumulation
in visceral and subcutaneous adipose tissue correlates with age. J. Allergy Clin.
Immunol. 119, S179.
Kanda, H., Tateya, S., Tamori, Y., Kotani, K., Hiasa, K., Kitazawa, R., Kitazawa, S., Miyachi, H.,
Maeda, S., Egashira, K., Kasuga, M., 2006. MCP-1 contributes to macrophage inﬁltra-
tion into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin.
Investig. 116, 1494–1505.
Karagiannides, I., Tchkonia, T., Dobson, D.E., Steppan, C.M., Cummins, P., Chan, G.,
Salvatori, K., Hadzopoulou-Cladaras, M., Kirkland, J.L., 2001. Altered expression of C/
EBP family members results in decreased adipogenesis with aging. Am. J. Physiol.
Regul. Integr. Comp. Physiol. 280, R1772–R1780.
Karakasilioti, I., Kamileri, I., Chatzinikolaou, G., Kosteas, T., Vergadi, E., Robinson, A.R.,
Tsamardinos, I., Rozgaja, T.A., Siakouli, S., Tsatsanis, C., Niedernhofer, L.J., Garinis,
G.A., 2013. DNA damage triggers a chronic autoinﬂammatory response, leading to
fat depletion in NER progeria. Cell Metab. 18, 403–415.
Karakelides, H., Irving, B.A., Short, K.R., O'Brien, P., Nair, K.S., 2010. Age, obesity, and sex
effects on insulin sensitivity and skeletal muscle mitochondrial function. Diabetes
59, 89–97.
Katic, M., Kennedy, A.R., Leykin, I., Norris, A., McGettrick, A., Gesta, S., Russell, S.J., Bluher,
M., Maratos-Flier, E., Kahn, C.R., 2007. Mitochondrial gene expression and increased
oxidative metabolism: role in increased lifespan of fat-speciﬁc insulin receptor
knock-out mice. Aging Cell 6, 827–839.Katsuda, T., Kosaka, N., Takeshita, F., Ochiya, T., 2013. The therapeutic potential of mesen-
chymal stem cell-derived extracellular vesicles. Proteomics 13, 1637–1653.
Kim, S.M., Lun, M., Wang, M., Senyo, S.E., Guillermier, C., Patwari, P., Steinhauser, M.L.,
2014. Loss of white adipose hyperplastic potential is associated with enhanced sus-
ceptibility to insulin resistance. Cell Metab. 20, 1049–1058.
Kirkland, J.L., Dobson, D.E., 1997. Preadipocyte function and aging: links between age-
related changes in cell dynamics and altered fat tissue function. J. Am. Geriatr. Soc.
45, 959–967.
Kirkland, J.L., Tchkonia, T., 2015. Clinical strategies and animal models for developing
senolytic agents. Exp. Gerontol. 68, 19–25.
Kirkland, J.L., Tchkonia, T., Pirtskhalava, T., Han, J., Karagiannides, I., 2002. Adipogenesis
and aging: does aging make fat go MAD? Exp. Gerontol. 37, 757–767.
Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kareholt, I., Winblad, B., Helkala, E.L.,
Tuomilehto, J., Soininen, H., Nissinen, A., 2005. Obesity and vascular risk factors at
midlife and the risk of dementia and Alzheimer disease. Arch. Neurol. 62, 1556–1560.
Klein, S., Fontana, L., Young, V.L., Coggan, A.R., Kilo, C., Patterson, B.W., Mohammed, B.S.,
2004. Absence of an effect of liposuction on insulin action and risk factors for coro-
nary heart disease. N. Engl. J. Med. 350, 2549–2557.
Koehler, E.M., Schouten, J.N., Hansen, B.E., van Rooij, F.J., Hofman, A., Stricker, B.H., Janssen,
H.L., 2012. Prevalence and risk factors of non-alcoholic fatty liver disease in the elder-
ly: results from the Rotterdam study. J. Hepatol. 57, 1305–1311.
Krizhanovsky, V., Yon, M., Dickins, R.A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L.,
Lowe, S.W., 2008. Senescence of activated stellate cells limits liver ﬁbrosis. Cell 134,
657–667.
Laberge, R.M., Sun, Y., Orjalo, A.V., Patil, C.K., Freund, A., Zhou, L., Curran, S.C., Davalos, A.R.,
Wilson-Edell, K.A., Liu, S., Limbad, C., Demaria, M., Li, P., Hubbard, G.B., Ikeno, Y.,
Javors, M., Desprez, P.Y., Benz, C.C., Kapahi, P., Nelson, P.S., Campisi, J., 2015. MTOR
regulates the pro-tumorigenic senescence-associated secretory phenotype by pro-
moting IL1A translation. Nat. Cell Biol. 17, 1049–1061.
Lakowa, N., Trieu, N., Flehmig, G., Lohmann, T., Schon, M.R., Dietrich, A., Zeplin, P.H.,
Langer, S., Stumvoll, M., Bluher, M., Kloting, N., 2015. Telomere length differences be-
tween subcutaneous and visceral adipose tissue in humans. Biochem. Biophys. Res.
Commun. 457, 426–432.
Linford, N.J., Beyer, R.P., Gollahon, K., Krajcik, R.A., Malloy, V.L., Demas, V., Burmer, G.C.,
Rabinovitch, P.S., 2007. Transcriptional response to aging and caloric restriction in
heart and adipose tissue. Aging Cell 6, 673–688.
Lottati, M., Kolka, C.M., Stefanovski, D., Kirkman, E.L., Bergman, R.N., 2009. Greater
omentectomy improves insulin sensitivity in nonobese dogs. Obesity 17, 674–680.
Lumeng, C.N., Bodzin, J.L., Saltiel, A.R., 2007. Obesity induces a phenotypic switch in adi-
pose tissue macrophage polarization. J. Clin. Invest. 117, 175–184.
Lumeng, C.N., Liu, J., Geletka, L., Delaney, C., Delproposto, J., Desai, A., Oatmen, K.,
Martinez-Santibanez, G., Julius, A., Garg, S., Yung, R.L., 2011. Aging is associated
with an increase in T cells and inﬂammatory macrophages in visceral adipose tissue.
J. Immunol. 187, 6208–6216.
Ma, X.H., Muzumdar, R., Yang, X.M., Gabriely, I., Berger, R., Barzilai, N., 2002. Aging is as-
sociated with resistance to effects of leptin on fat distribution and insulin action.
J. Gerontol. Ser. A Biol. Med. Sci. 57, B225–B231.
Manolopoulos, K.N., Karpe, F., Frayn, K.N., 2010. Gluteofemoral body fat as a determinant
of metabolic health. Int. J. Obes. 34, 949–959.
Mansilla, E., Diaz Aquino, V., Zambon, D., Marin, G.H., Martire, K., Roque, G., Ichim, T.,
Riordan, N.H., Patel, A., Sturla, F., Larsen, G., Spretz, R., Nunez, L., Soratti, C., Ibar, R.,
van Leeuwen, M., Tau, J.M., Drago, H., Maceira, A., 2011. Could metabolic syndrome,
lipodystrophy, and aging be mesenchymal stem cell exhaustion syndromes? Stem
Cells Int. 943216, 2011.
Marcus, R.L., Addison, O., Kidde, J.P., Dibble, L.E., Lastayo, P.C., 2010. Skeletal muscle fat in-
ﬁltration: impact of age, inactivity, and exercise. J. Nutr. Health Aging 14, 362–366.
Martin-Montalvo, A., Mercken, E.M., Mitchell, S.J., Palacios, H.H., Mote, P.L., Scheibye-
Knudsen, M., Gomes, A.P., Ward, T.M., Minor, R.K., Blouin, M.J., Schwab, M., Pollak,
M., Zhang, Y., Yu, Y., Becker, K.G., Bohr, V.A., Ingram, D.K., Sinclair, D.A., Wolf, N.S.,
Spindler, S.R., Bernier, M., de Cabo, R., 2013. Metformin improves healthspan and
lifespan in mice. Nat. Commun. 4, 2192.
Mattson, M.P., 2010. Perspective: does brown fat protect against diseases of aging? Age-
ing Res. Rev. 9, 69–76.
Mazereeuw-Hautier, J., Wilson, L.C., Mohammed, S., Smallwood, D., Shackleton, S.,
Atherton, D.J., Harper, J.I., 2007. Hutchinson–Gilford progeria syndrome: clinical ﬁnd-
ings in three patients carrying the G608G mutation in LMNA and review of the liter-
ature. Br. J. Dermatol. 156, 1308–1314.
McLaughlin, T., Allison, G., Abbasi, F., Lamendola, C., Reaven, G., 2004. Prevalence of insulin
resistance and associated cardiovascular disease risk factors among normal weight,
overweight, and obese individuals. Metab. Clin. Exp. 53, 495–499.
Menke, A., Casagrande, S., Geiss, L., Cowie, C.C., 2015. Prevalence of and trends in
diabetes among adults in the United States, 1988–2012. J. Am. Med. Assoc. 314,
1021–1029.
Minamino, T., Orimo, M., Shimizu, I., Kunieda, T., Yokoyama, M., Ito, T., Nojima, A.,
Nabetani, A., Oike, Y., Matsubara, H., Ishikawa, F., Komuro, I., 2009. A crucial role for
adipose tissue p53 in the regulation of insulin resistance. Nat. Med. 15, 1082–1087.
Minor, R.K., Lopez, M., Younts, C.M., Jones, B., Pearson, K.J., Anson, R.M., Dieguez, C., de
Cabo, R., 2011. The arcuate nucleus and neuropeptide Y contribute to the
antitumorigenic effect of calorie restriction. Aging Cell 10, 483–492.
Mori, M.A., Raghavan, P., Thomou, T., Boucher, J., Robida-Stubbs, S., Macotela, Y., Russell,
S.J., Kirkland, J.L., Blackwell, T.K., Kahn, C.R., 2012. Role of microRNA processing in ad-
ipose tissue in stress defense and longevity. Cell Metab. 16, 336–347.
Mori, M.A., Thomou, T., Boucher, J., Lee, K.Y., Lallukka, S., Kim, J.K., Torriani, M., Yki-
Jarvinen, H., Grinspoon, S.K., Cypess, A.M., Kahn, C.R., 2014. AlteredmiRNA processing
disrupts brown/white adipocyte determination and associates with lipodystrophy.
J. Clin. Invest. 124, 3339–3351.
105A.K. Palmer, J.L. Kirkland / Experimental Gerontology 86 (2016) 97–105Muzumdar, R., Allison, D.B., Huffman, D.M., Ma, X., Atzmon, G., Einstein, F.H., Fishman, S.,
Poduval, A.D., McVei, T., Keith, S.W., Barzilai, N., 2008. Visceral adipose tissue modu-
lates mammalian longevity. Aging Cell 7, 438–440.
Naveiras, O., Nardi, V., Wenzel, P.L., Hauschka, P.V., Fahey, F., Daley, G.Q., 2009. Bone-
marrow adipocytes as negative regulators of the haematopoietic microenvironment.
Nature 460, 259–263.
Okada-Iwabu, M., Yamauchi, T., Iwabu, M., Honma, T., Hamagami, K., Matsuda, K.,
Yamaguchi, M., Tanabe, H., Kimura-Someya, T., Shirouzu, M., Ogata, H., Tokuyama,
K., Ueki, K., Nagano, T., Tanaka, A., Yokoyama, S., Kadowaki, T., 2013. A small-
molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 503,
493–499.
Ortega Martinez de Victoria, E., Xu, X., Koska, J., Francisco, A.M., Scalise, M., Ferrante Jr.,
A.W., Krakoff, J., 2009. Macrophage content in subcutaneous adipose tissue: associa-
tions with adiposity, age, inﬂammatory markers, and whole-body insulin action in
healthy Pima Indians. Diabetes 58, 385–393.
Palmer, A.K., Tchkonia, T., LeBrasseur, N.K., Chini, E.N., Xu, M., Kirkland, J.L., 2015. Cellular
senescence in type 2 diabetes: a therapeutic opportunity. Diabetes 64, 2289–2298.
Parrinello, S., Coppe, J.P., Krtolica, A., Campisi, J., 2005. Stromal–epithelial interactions in
aging and cancer: senescent ﬁbroblasts alter epithelial cell differentiation. J. Cell Sci.
118, 485–496.
Picard, F., Guarente, L., 2005. Molecular links between aging and adipose tissue. Int.
J. Obes. 29 (Suppl. 1), S36–S39.
Pincus, Z., Smith-Vikos, T., Slack, F.J., 2011. MicroRNA predictors of longevity in
Caenorhabditis elegans. PLoS Genet. 7, e1002306.
Preis, S.R., Massaro, J.M., Robins, S.J., Hoffmann, U., Vasan, R.S., Irlbeck, T., Meigs, J.B.,
Sutherland, P., D'Agostino Sr., R.B., O'Donnell, C.J., Fox, C.S., 2010. Abdominal subcuta-
neous and visceral adipose tissue and insulin resistance in the Framingham heart
study. Obesity 18, 2191–2198.
Raj, A., van Oudenaarden, A., 2008. Nature, nurture, or chance: stochastic gene expression
and its consequences. Cell 135, 216–226.
Ranganath, S.H., Levy, O., Inamdar, M.S., Karp, J.M., 2012. Harnessing the mesenchymal
stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 10,
244–258.
Rogers, N.H., Landa, A., Park, S., Smith, R.G., 2012. Aging leads to a programmed loss of
brown adipocytes in murine subcutaneous white adipose tissue. Aging Cell 11,
1074–1083.
Romero-Corral, A., Somers, V.K., Sierra-Johnson, J., Thomas, R.J., Collazo-Clavell, M.L.,
Korinek, J., Allison, T.G., Batsis, J.A., Sert-Kuniyoshi, F.H., Lopez-Jimenez, F., 2008. Accu-
racy of body mass index in diagnosing obesity in the adult general population. Int.
J. Obes. 32, 959–966.
Roos, C.M., Zhang, B., Palmer, A.K., Ogrodnik, M.B., Pirtskhalava, T., Thalji, N.M., Hagler, M.,
Jurk, D., Smith, L.A., Casaclang-Verzosa, G., Zhu, Y., Schafer, M.J., Tchkonia, T., Kirkland,
J.L., Miller, J.D., 2016. Chronic senolytic treatment alleviates established vasomotor
dysfunction in aged or atherosclerotic mice. Aging Cell.
Saito, M., Okamatsu-Ogura, Y., Matsushita, M., Watanabe, K., Yoneshiro, T., Nio-Kobayashi,
J., Iwanaga, T., Miyagawa, M., Kameya, T., Nakada, K., Kawai, Y., Tsujisaki, M., 2009.
High incidence ofmetabolically active brown adipose tissue in healthy adult humans:
effects of cold exposure and adiposity. Diabetes 58, 1526–1531.
Samanic, C., Gridley, G., Chow,W.H., Lubin, J., Hoover, R.N., Fraumeni Jr., J.F., 2004. Obesity
and cancer risk amongwhite and black United States veterans. Cancer Causes Control
15, 35–43.
Schipper, B.M., Marra, K.G., Zhang, W., Donnenberg, A.D., Rubin, J.P., 2008. Regional ana-
tomic and age effects on cell function of human adipose-derived stem cells. Ann.
Plast. Surg. 60, 538–544.
Sepe, A., Tchkonia, T., Thomou, T., Zamboni, M., Kirkland, J.L., 2011. Aging and regional dif-
ferences in fat cell progenitors - a mini-review. Gerontology 57, 66–75.
Sjostrom, L., Narbro, K., Sjostrom, C.D., Karason, K., Larsson, B., Wedel, H., Lystig, T.,
Sullivan, M., Bouchard, C., Carlsson, B., Bengtsson, C., Dahlgren, S., Gummesson, A.,
Jacobson, P., Karlsson, J., Lindroos, A.K., Lonroth, H., Naslund, I., Olbers, T., Stenlof, K.,
Torgerson, J., Agren, G., Carlsson, L.M., 2007. Swedish obese subjects, S. Effects of bar-
iatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med. 357, 741–752.
Snijder, M.B., Dekker, J.M., Visser, M., Yudkin, J.S., Stehouwer, C.D., Bouter, L.M., Heine, R.J.,
Nijpels, G., Seidell, J.C., 2003. Larger thigh and hip circumferences are associated with
better glucose tolerance: the Hoorn study. Obes. Res. 11, 104–111.
Storer, M., Mas, A., Robert-Moreno, A., Pecoraro, M., Ortells, M.C., Di Giacomo, V., Yosef, R.,
Pilpel, N., Krizhanovsky, V., Sharpe, J., Keyes, W.M., 2013. Senescence is a develop-
mental mechanism that contributes to embryonic growth and patterning. Cell 155,
1119–1130.
Stout, M.B., Tchkonia, T., Pirtskhalava, T., Palmer, A.K., List, E.O., Berryman, D.E., Lubbers,
E.R., Escande, C., Spong, A., Masternak, M.M., Oberg, A.L., LeBrasseur, N.K., Miller,
R.A., Kopchick, J.J., Bartke, A., Kirkland, J.L., 2014. Growth hormone action predicts
age-related white adipose tissue dysfunction and senescent cell burden in mice.
Aging 6, 575–586.
Stout, M.B., Steyn, F.J., Jurczak, M.J., Camporez, J.G., Zhu, Y., Hawse, J.R., Jurk, D., Palmer,
A.K., Xu, M., Pirtskhalava, T., Evans, G.L., de Souza Santos, R., Frank, A.P., White, T.A.,
Monroe, D.G., Singh, R.J., Casaclang-Verzosa, G., Miller, J.D., Clegg, D.J., LeBrasseur,
N.K., von Zglinicki, T., Shulman, G.I., Tchkonia, T., Kirkland, J.L., 2016. 17alpha-
estradiol alleviates age-related metabolic and inﬂammatory dysfunction in male
mice without inducing feminization. J. Gerontol. Ser. A Biol. Med. Sci.
Strioga, M., Viswanathan, S., Darinskas, A., Slaby, O., Michalek, J., 2012. Same or not the
same? Comparison of adipose tissue-derived versus bone marrow-derived mesen-
chymal stem and stromal cells. Stem Cells Dev. 21, 2724–2752.
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., Gerich, J.E., 1995. Metabolic effects of
metformin in non-insulin-dependent diabetesmellitus. N. Engl. J. Med. 333, 550–554.
Tan, C.Y., Virtue, S., Bidault, G., Dale, M., Hagen, R., Grifﬁn, J.L., Vidal-Puig, A., 2015. Brown
adipose tissue thermogenic capacity is regulated by Elovl6. Cell Rep. 13, 2039–2047.Tchkonia, T., Corkey, B.E., Kirkland, J.L., 2006a. Current views of the fat cell as an endocrine
cell: lipotoxicity. overweight and the metabolic syndrome: from bench to bedside
(Endocrine Updates).
Tchkonia, T., Giorgadze, N., Pirtskhalava, T., Thomou, T., DePonte, M., Koo, A., Forse, R.A.,
Chinnappan, D., Martin-Ruiz, C., von Zglinicki, T., Kirkland, J.L., 2006b. Fat depot-
speciﬁc characteristics are retained in strains derived from single human
preadipocytes. Diabetes 55, 2571–2578.
Tchkonia, T., Morbeck, D.E., Von Zglinicki, T., Van Deursen, J., Lustgarten, J., Scrable, H.,
Khosla, S., Jensen, M.D., Kirkland, J.L., 2010. Fat tissue, aging, and cellular senescence.
Aging Cell 9, 667–684.
Tchkonia, T., Thomou, T., Zhu, Y., Karagiannides, I., Pothoulakis, C., Jensen, M.D., Kirkland,
J.L., 2013a. Mechanisms and metabolic implications of regional differences among fat
depots. Cell Metab. 17, 644–656.
Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J., Kirkland, J.L., 2013b. Cellular senescence
and the senescent secretory phenotype: therapeutic opportunities. J. Clin. Invest. 123,
966–972.
Tilg, H., Moschen, A.R., 2006. Adipocytokines: mediators linking adipose tissue, inﬂamma-
tion and immunity. Nat. Rev. Immunol. 6, 772–783.
Timmons, J.A., Pedersen, B.K., 2009. The importance of brown adipose tissue. N. Engl.
J. Med. 361, 415–416 (author reply 418-421).
Tran, T.T., Yamamoto, Y., Gesta, S., Kahn, C.R., 2008. Beneﬁcial effects of subcutaneous fat
transplantation on metabolism. Cell Metab. 7, 410–420.
Unger, R.H., Zhou, Y.T., 2001. Lipotoxicity of beta-cells in obesity and in other causes of
fatty acid spillover. Diabetes 50 (Suppl. 1), S118–S121.
Valdes, A.M., Andrew, T., Gardner, J.P., Kimura, M., Oelsner, E., Cherkas, L.F., Aviv, A.,
Spector, T.D., 2005. Obesity, cigarette smoking, and telomere length in women. Lan-
cet 366, 662–664.
Valle, A., Guevara, R., Garcia-Palmer, F.J., Roca, P., Oliver, J., 2008. Caloric restriction retards
the age-related decline in mitochondrial function of brown adipose tissue. Rejuvena-
tion Res. 11, 597–604.
van Marken Lichtenbelt, W.D., Vanhommerig, J.W., Smulders, N.M., Drossaerts, J.M.,
Kemerink, G.J., Bouvy, N.D., Schrauwen, P., Teule, G.J., 2009. Cold-activated brown ad-
ipose tissue in healthy men. N. Engl. J. Med. 360, 1500–1508.
Verstovsek, S., Kantarjian, H., Mesa, R.A., Pardanani, A.D., Cortes-Franco, J., Thomas, D.A.,
Estrov, Z., Fridman, J.S., Bradley, E.C., Erickson-Viitanen, S., Vaddi, K., Levy, R., Tefferi,
A., 2010. Safety and efﬁcacy of INCB018424, a JAK1 and JAK2 inhibitor, in myeloﬁbro-
sis. N. Engl. J. Med. 363, 1117–1127.
Virtanen, K.A., Lidell, M.E., Orava, J., Heglind, M., Westergren, R., Niemi, T., Taittonen, M.,
Laine, J., Savisto, N.J., Enerback, S., Nuutila, P., 2009. Functional brown adipose tissue
in healthy adults. N. Engl. J. Med. 360, 1518–1525.
Wolk, A., Gridley, G., Svensson, M., Nyren, O., McLaughlin, J.K., Fraumeni, J.F., Adam, H.O.,
2001. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control
12, 13–21.
Wu, D., Ren, Z., Pae, M., Guo, W., Cui, X., Merrill, A.H., Meydani, S.N., 2007. Aging up-
regulates expression of inﬂammatory mediators in mouse adipose tissue.
J. Immunol. 179, 4829–4839.
Wu, J., Bostrom, P., Sparks, L.M., Ye, L., Choi, J.H., Giang, A.H., Khandekar, M., Virtanen, K.A.,
Nuutila, P., Schaart, G., Huang, K., Tu, H., van Marken Lichtenbelt, W.D., Hoeks, J.,
Enerback, S., Schrauwen, P., Spiegelman, B.M., 2012. Beige adipocytes are a distinct
type of thermogenic fat cell in mouse and human. Cell 150, 366–376.
Wyles, C.C., Houdek, M.T., Crespo-Diaz, R.J., Norambuena, G.A., Stalboerger, P.G., Terzic, A.,
Behfar, A., Sierra, R.J., 2015. Adipose-derived mesenchymal stem cells are phenotyp-
ically superior for regeneration in the setting of osteonecrosis of the femoral head.
Clin. Orthop. Relat. Res. 473, 3080–3090.
Xu, M., Palmer, A.K., Ding, H., Weivoda, M.M., Pirtskhalava, T., White, T.A., Sepe, A.,
Johnson, K.O., Stout, M.B., Giorgadze, N., Jensen, M.D., LeBrasseur, N.K., Tchkonia, T.,
Kirkland, J.L., 2015a. Targeting senescent cells enhances adipogenesis and metabolic
function in old age. eLife 4.
Xu, M., Tchkonia, T., Ding, H., Ogrodnik, M., Lubbers, E.R., Pirtskhalava, T., White, T.A.,
Johnson, K.O., Stout, M.B., Mezera, V., Giorgadze, N., Jensen, M.D., LeBrasseur, N.K.,
Kirkland, J.L., 2015b. JAK inhibition alleviates the cellular senescence-associated se-
cretory phenotype and frailty in old age. Proc. Natl. Acad. Sci. U. S. A. 112,
E6301–E6310.
Yamashita, H., Sato, Y., Mori, N., 1999. Difference in induction of uncoupling protein genes
in adipose tissues between young and old rats during cold exposure. FEBS Lett. 458,
157–161.
Yamauchi, T., Kadowaki, T., 2013. Adiponectin receptor as a key player in healthy longev-
ity and obesity-related diseases. Cell Metab. 17, 185–196.
Yoneshiro, T., Aita, S., Matsushita, M., Okamatsu-Ogura, Y., Kameya, T., Kawai, Y.,
Miyagawa, M., Tsujisaki, M., Saito, M., 2011. Age-related decrease in cold-activated
brown adipose tissue and accumulation of body fat in healthy humans. Obesity 19,
1755–1760.
Zhu, Y., Tchkonia, T., Fuhrmann-Stroissnigg, H., Dai, H.M., Ling, Y.Y., Stout, M.B.,
Pirtskhalava, T., Giorgadze, N., Johnson, K.O., Giles, C.B., Wren, J.D., Niedernhofer,
L.J., Robbins, P.D., Kirkland, J.L., 2015a. Identiﬁcation of a novel senolytic agent,
navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell.
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A.C., Ding, H., Giorgadze, N., Palmer, A.K.,
Ikeno, Y., Hubbard, G.B., Lenburg, M., O' Hara, S.P., LaRusso, N.F., Miller, J.D., Roos,
C.M., Verzosa, G.C., LeBrasseur, N.K., Wren, J.D., Farr, J.N., Khosla, S., Stout, M.B.,
McGowan, S.J., Fuhrmann-Stroissnigg, H., Gurkar, A.U., Zhao, J., Colangelo, D.,
Dorronsoro, A., Ling, Y.Y., Barghouthy, A.S., Navarro, D.C., Sano, T., Robbins, P.D.,
Niedernhofer, L.J., Kirkland, J.L., 2015b. The Achilles' heel of senescent cells: from
transcriptome to senolytic drugs. Aging Cell 14, 644–658.
Zuk, P.A., Zhu, M., Ashjian, P., De Ugarte, D.A., Huang, J.I., Mizuno, H., Alfonso, Z.C., Fraser,
J.K., Benhaim, P., Hedrick, M.H., 2002. Human adipose tissue is a source of multipotent
stem cells. Mol. Biol. Cell 13, 4279–4295.
